NEW ORLEANS--(BUSINESS WIRE)--Today, New Orleans based biotech startup MiniVax, Inc. (MiniVax), a company focused on preventing and treating opportunistic infections, announced Gordon Brown, Ph.D. as the newest addition to its Scientific Advisory Board. Dr. Brown has over 15 years of experience in fungal infection and immunology research and will help further develop MiniVax’s novel vaccine for preventing Pneumocystis pneumonia (PCP), a deadly fungal infection of the lungs that predominantly affects immunocompromised patients such as HIV/AIDS patients. Dr. Brown sits as the Sixth Century Chair in Immunology at the University of Aberdeen and is Co-Director of the Aberdeen Fungal Group, which is one of the largest fungal groups in the world.
